Abstract
Caffeine is a methylxanthine, clinically used to treat apnea in preterm infants.However, it has been found that the drug also has a role in reducing the incidence of bronchopulmonary dysplasia(BPD)in preterm infants in recent years.It may be related to improvement of lung function, improvement of extubation success rate and shortening of ventilator assisted ventilation time.Further study found that caffeine could play a protective role in the prevention and control of BPD by antagonistic adenosine receptors, inhibiting inflammatory mediators, inhibiting the transforming growth factors-β1, and inhibiting matrix metalloproteinases. Key words: Caffeine; Premature infants; Bronchopulmonary dysplasia
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
